PDA Biosimilars Workshop Report (September 27-28, 2018)-Getting It Right the First Time for Biosimilar Marketing Applications.
Continuous processing
Downstream processing
FDA
Facility risk mitigation
Health Canada
Novel format molecules
PEI
Regulatory agencies
Regulatory perspective
Resin lifetime
Strategy
Submission
Upstream processing
Viral Clearance Symposium
Viral clearance
Viral safety
Journal
PDA journal of pharmaceutical science and technology
ISSN: 1948-2124
Titre abrégé: PDA J Pharm Sci Technol
Pays: United States
ID NLM: 9439538
Informations de publication
Date de publication:
Historique:
pubmed:
21
4
2019
medline:
9
4
2020
entrez:
21
4
2019
Statut:
ppublish
Résumé
This workshop report summarizes the presentations, the breakout session outcomes, and the speaker panel discussions from the PDA Biosimilars Workshop held September 27-28, 2018, in Washington, DC. This format was deliberately selected for the workshop with the expectation of delivering a post-workshop paper on current best practices and existing challenges for sponsors. The event, co-chaired by Dr. Stephan Krause (AstraZeneca Biologics) and Dr. Emanuela Lacana (CDER/FDA), was attended by 140 agency and industry representatives. The workshop was separated into three major sessions P1: Regulatory Perspective, P2: Challenges in Biosimilar Development, and P3: Demonstrating Analytical Similarity. Each of the three sessions started with agency and industry presentations. Participants then split into two concurrent roundtable discussion groups to hear the answers to questions that had been provided to all participants one week prior to the event. The sessions were recorded. This paper provides consolidated answers to specific case studies for current challenges to sponsors and agencies. In addition, the panel discussion notes following each breakout roundtable session, as well as brief talk summaries of all speakers, are provided. The first session explored the challenges encountered with submission of biosimilar marketing applications from the perspectives of regulatory agencies. Expectations for a successful submission of the chemistry, manufacturing, and controls (CMC) information were described. The second session addressed high-level technical challenges and how to avoid pitfalls frequently encountered during biosimilar candidate development, including data quality expectations, creation of the final control strategy, and strategic choices necessary for candidate selection and development. Both regulatory perspectives and industry experience were shared. The last session explored the use of statistical tools to provide meaningful contributions to the demonstration of analytical similarity. The presentations highlighted common issues and practical challenges that arise during the application of statistical tools.
Identifiants
pubmed: 31004040
pii: pdajpst.2019.010215
doi: 10.5731/pdajpst.2019.010215
doi:
Substances chimiques
Biosimilar Pharmaceuticals
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
401-416Informations de copyright
© PDA, Inc. 2019.